



Original Effective Date: 12/13/2017
Current Effective Date: 12/01/2025
Last P&T Approval/Version: 10/29/2025
Next Review Due By: 10/2025
Policy Number: C11728-A

Iluvien (fluocinolone acetonide intravitreal implant)

PRODUCTS AFFECTED

Iluvien (fluocinolone acetonide intravitreal implant)

COVERAGE POLICY

Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Coverage Guideline must be read in its entirety to determine coverage eligibility, if any. This Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide Molina Healthcare complete medical rationale when requesting any exceptions to these guidelines.

Documentation Requirements:

Molina Healthcare reserves the right to require that additional documentation be made available as part of its coverage determination; quality improvement; and fraud; waste and abuse prevention processes. Documentation required may include, but is not limited to, patient records, test results and credentials of the provider ordering or performing a drug or service. Molina Healthcare may deny reimbursement or take additional appropriate action if the documentation provided does not support the initial determination that the drugs or services were medically necessary, not investigational or experimental, and otherwise within the scope of benefits afforded to the member, and/or the documentation demonstrates a pattern of billing or other practice that is inappropriate or excessive.

DIAGNOSIS:

Diabetic Macular Edema (DME), Posterior chronic non-infectious uveitis

REQUIRED MEDICAL INFORMATION:

This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. If a drug within this policy receives an updated FDA label within the last 180 days, medical necessity for the member will be reviewed using the updated FDA label information along with state and federal requirements, benefit being administered and formulary preferencing. Coverage will be determined on a case-by-case basis until the criteria can be updated through Molina Healthcare, Inc. clinical governance. Additional information may be required on a case-by-case basis to allow for adequate review. When the requested drug product for coverage is dosed by weight, body surface area or other member specific measurement, this data element is required as part of the medical necessity review. The Pharmacy and Therapeutics Committee has determined that the drug benefit shall be a mandatory generic and that generic drugs will be dispensed whenever available.

A. DIABETIC MACULAR EDEMA (DME):

1. Documented diagnosis of Diabetic Macular Edema (DME)
AND

Drug and Biologic Coverage Criteria

2. Documentation of baseline visual status with notation of eye being treated [DOCUMENTATION REQUIRED]
AND
3. Documentation of an inadequate response (defined as 1-2 injections with minimal to no improvement), clinically significant adverse effects, or contraindication to bevacizumab OR bevacizumab is indicated by the provider as unavailable and there is documentation of an inadequate response, serious side effects or contraindication to ranibizumab
AND
4. Documentation of an inadequate response to an appropriate trial of intravitreal glucocorticoids (i.e., triamcinolone)
AND
5. Member was previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure
AND
6. Prescriber attests or clinical reviewer has found that Iluvien (fluocinolone acetonide intravitreal implant) will NOT be administered simultaneously (bilateral implantation)
MOLINA REVIEWER NOTE: Simultaneous bilateral implantation should not be performed to limit the potential for bilateral post-operative infection (due to the risk of, and resistance to infections reduced by corticosteroids)
AND
7. Prescriber attests to (or the clinical reviewer has found that) the member not having any FDA labeled contraindications that haven't been addressed by the prescriber within the documentation submitted for review [Contraindications to Iluvien (fluocinolone acetonide intravitreal implant) include: ocular or periocular infections, glaucoma, and hypersensitivity to any component of the product.]

B. NON-INFECTIOUS UVEITIS:

1. Documented diagnosis of non-infectious posterior segment uveitis
AND
2. Documentation of member's baseline best-corrected visual acuity (BCVA) in order to measure efficacy with notation of eye(s) being treated
AND
3. Documentation of an inadequate response (appropriate trial period included), serious side effects, or contraindication to formulary topical glucocorticoids OR an intravitreal steroid (e.g., triamcinolone, dexamethasone) OR a systemic corticosteroid
AND
4. Documented trial and failure, serious side effects, or contraindication to an anti-metabolite (e.g., methotrexate, azathioprine, mycophenolate) OR a calcineurin inhibitor (e.g., cyclosporine, tacrolimus)
AND
5. Member was previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure
AND
6. Prescriber attests to (or the clinical reviewer has found that) the member not having any FDA labeled contraindications that haven't been addressed by the prescriber within the documentation submitted for review [Contraindications to Iluvien (fluocinolone acetonide intravitreal implant) include: ocular or periocular infections, glaucoma, and hypersensitivity to any component of the product.]

CONTINUATION OF THERAPY:

A. DIABETIC MACULAR EDEMA (DME):

1. Reauthorization request is for the same eye as initial authorization AND at least 36 months have passed since last Iluvien administration.

NOTE: The continuation of therapy criteria is only for the same previously treated eye. If member

Drug and Biologic Coverage Criteria

has developed condition in an untreated eye, a new request should be submitted and meet all initial coverage criteria.

AND

2. Documentation or improvement of stabilization of disease state (e.g., macular edema, etc.) and visual status [DOCUMENTATION REQUIRED]
AND
3. Prescriber attests member is likely to benefit from re-treatment without being exposed to significant risk according to Prescriber's clinical judgement
AND
4. Prescriber attests to or clinical reviewer has found no evidence of intolerable adverse effects or drug toxicity (e.g., cataracts, increased intraocular pressure, hypotony, endophthalmitis)

B. NON-INFECTIOUS UVEITIS:

1. Reauthorization request is for the same eye as initial authorization AND at least 36 months have passed since last Iluvien administration
NOTE: The continuation of therapy criteria is only for the same previously treated eye. If member has developed condition in an untreated eye, a new request should be submitted and meet all initial coverage criteria.
AND
2. Documentation of positive response to treatment as indicated by lack of recurrence, greater than 15 letters (3 lines) in BCVA from baseline or the member achieved driving visual acuity, or visual acuity maintained to at least 50% of the best recorded following diagnosis of uveitis
AND
3. Prescriber attests member is likely to benefit from re-treatment without being exposed to significant risk, according to Prescriber's clinical judgment
AND
4. Prescriber attests to or clinical reviewer has found no evidence of intolerable adverse effects or drug toxicity (e.g., cataracts, increased intraocular pressure, hypotony, endophthalmitis)

DURATION OF APPROVAL:

Initial authorization: 36 months, Continuation of therapy: 36 months

PRESCRIBER REQUIREMENTS:

Prescribed by or in consultation with a board-certified ophthalmologist, ophthalmic surgeon or retinal specialist experienced in the administration of intravitreal implants, or other specialist in uveal eye disease. [If prescribed in consultation, consultation notes must be submitted with initial request and reauthorization requests]

AGE RESTRICTIONS:

18 years of age and older

QUANTITY:

ONE implant per eye per 36 months

PLACE OF ADMINISTRATION:

The recommendation is that intravitreal injection medications in this policy will be for pharmacy or medical benefit coverage and the implant administered in a place of service that is a non-hospital facility-based location.

DRUG INFORMATION

ROUTE OF ADMINISTRATION:

Ophthalmic intravitreal injection

Molina Healthcare, Inc. confidential and proprietary © 2025

This document contains confidential and proprietary information of Molina Healthcare and cannot be reproduced, distributed, or printed without written permission from Molina Healthcare. This page contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with Molina Healthcare.

Drug and Biologic Coverage Criteria

DRUG CLASS:

Ophthalmic Steroid

FDA-APPROVED USES:

Indicated for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure and the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.

COMPENDIAL APPROVED OFF-LABELED USES:

None

APPENDIX

APPENDIX:

Diabetic Macular Edema (DME): Leakage of fluid from retinal blood vessels which cause the macula to swell

Diabetic Retinopathy (DR): The progressive damage to the blood vessels in the back of the eye

Intravitreal: refers to that which is injected into the eye's vitreous humor between the lens and the retina. Intravitreal implants deliver a continuous concentration of drug over a prolonged period of time. Intravitreal corticosteroid implants are being studied for a variety of eye conditions leading to macular edema, including uveitis, diabetic retinopathy, and retinal venous occlusions. The goal of therapy is to reduce the inflammatory process in the eye while minimizing the adverse effects of the therapeutic regimen.

Phakic: An eye containing the natural lens

Pseudophakic: An eye in which a natural lens is replaced with an artificial lens implant

Retinopathy: Damage to the retina

Vascular Endothelial Growth Factor (VEGF): A chemical signal produced by the body's cells that stimulates growth of new blood vessels.

Uveitis: An inflammation of part or all of the uvea, the middle (vascular) tunic of the eye and commonly involving the other tunics (the sclera and cornea and the retina)

BACKGROUND AND OTHER CONSIDERATIONS

BACKGROUND:

Ehlers et al. (2022) wrote a report by the American Academy of Ophthalmology reviewing the safety and efficacy evidence for diabetic macular edema (DME) treatments. The review revealed that the current intravitreal pharmacotherapies, such as anti-VEGF injections and corticosteroid implants, are safe and effective. Corticosteroid implants carry a higher risk of increased intraocular pressure (IOP) related adverse effects compared to anti-VEGF therapeutics. As there is a lack of robust comparative analysis evidence between anti-VEGF, corticosteroid implants, and combination therapies the authors emphasize that the choice of therapy is up to physician discretion and that access to all therapeutic options is imperative for appropriate care of individual patients.

Brambati et al (2022) conducted a retrospective cohort study on ten eyes from ten subjects with type 2 non-proliferative diabetic retinopathy and DME at baseline treated with Iluvien. A minimum of two 6 × 6-mm optical coherence tomography angiography (OCTA) scans were required to ensure that all cases had

Drug and Biologic Coverage Criteria

a baseline OCTA and an OCTA performed at 4 months of follow-up. Mean parafoveal perfusion density (PD) at baseline was $64.1 \pm 1.8\%$ at baseline, increasing to $66.1 \pm 2.9\%$ ($p = 0.013$) at the 4-month follow-up visit. In the qualitative assessment, 60 regions (10 areas for each subject) were graded to assess changes in retinal perfusion between the baseline and follow-up visits. This assessment revealed that 24 regions (40.0%) were characterized by a qualitative increase in perfusion after treatment, while 22 (36.7%) and 14 (23.3%) regions were featured by a stability and reduction in retinal perfusion, respectively.

Mansour et al. (2021) conducted a 24-month prospective observational study of participants treated with Iluvien to confirm safety and efficacy of the fluocinolone acetonide (FAc) intravitreal implant. Ninety-five participants (115 study eyes) were included in the study. The participants were previously steroid-challenged patients for up to 36 months pre-FAc and followed 24 months post-FAc implant. Mean IOP for the overall population remained stable post-FAc compared with pre-FAc implant. IOP-lowering therapies necessary were as follows, two trabeculectomies and four IOP-lowering surgeries post-FAc. Mean visual acuity was stable post-FAc (mean improvement of 1-3 letters) and fewer DME treatments were required per year following FAc implant. Mean central subfield thickness was significantly reduced at 24 months post-FAc implant ($p < 0.001$) and the percentage of patients with central subfield thickness $\leq 300 \mu\text{m}$ was significantly increased ($p = 0.041$). Positive efficacy outcomes were noted after treatment, with stabilization of vision and reduction in inflammation. The FAc implant is a favorable treatment option for DME, especially when administered after a prior steroid challenge (Clinicaltrials.gov).

Adan et al. (2020) reviewed current literature and clinical practice to compile a clinical decision criterion to identify recurrent diabetic macular edema patients suitable for Iluvien, complete with follow up recommendations. The authors analyzed the data and concluded there is progressive and continuous improvement of the macula and visual outcomes with FAc. In response to clinical trial and real world evidence, the recommendations conclude that FAc implants should be positioned earlier in the DME treatment algorithm for those who have received one or two previous dexamethasone injections and continue to show presence of DME 3-4 post injection, as this indicates the patient has reoccurring DME and will require continued injections for a long period of time; moving to the FAc implant treatment will prevent patients from being subjected to a high number of unnecessary injections of suboptimal treatment. The recommendations conclude the main patient profile that could benefit from the FAc implant is for patients with a complete anatomical response after one injection of dexamethasone implant for those patients whom the retina layers are preserved; however, the FAc implant has shown efficacy even in those patients that had insufficient response to previous therapies.

Rittiphairoj et al. (2020), in a Cochrane review, compared intravitreal steroid therapy to other treatments for DME. The systematic review included 10 RCTs (4348 participants, 4505 eyes) that compared any type of intravitreal steroids as monotherapy to any other intervention (e.g., observation, laser photocoagulation, anti-VEGF for DME). These trials compared intravitreal steroid therapies to other treatments such as intravitreal anti-VEGF therapy, laser photocoagulation, and sham injection. One study (560 eyes) compared intravitreal fluocinolone implant 0.19mg to sham. At 12 months, there was moderate certainty that fluocinolone improved visual acuity slightly more. Fluocinolone was more likely than placebo to increase visual acuity by three or more lines at 12 months, according to evidence of moderate certainty. Fluocinolone also increased the risk of cataract progression (participants = 335; moderate-certainty evidence), which occurred in approximately 8 out of 10 participants, and the use of IOP-lowering medications (participants = 558; moderate-certainty evidence), which was required in 2 to 3 out of 10 participants. The authors concluded that intravitreal steroids may improve vision in patients with DME compared to placebo or control. In most comparisons, the effects were negligible, approximately one line

Molina Healthcare, Inc. confidential and proprietary © 2025

This document contains confidential and proprietary information of Molina Healthcare and cannot be reproduced, distributed, or printed without written permission from Molina Healthcare. This page contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with Molina Healthcare.

Drug and Biologic Coverage Criteria

of vision or less. More evidence is available when comparing dexamethasone or fluocinolone implants to placebo, however evidence comparing dexamethasone with anti-VEGF therapy is limited and inconsistent. Any benefits should be evaluated against IOP rise, usage of IOP-lowering medication, and cataract advancement in phakic patients. Glaucoma surgery is also increasing but remains rare. Chakravarthy et al. (2019) conducted a multicenter open-label observational study collecting real-world data on the safety and effectiveness of five hundred and sixty-three patients (593 eyes) treated with the fluocinolone acetonide (FAC) intravitreal implant. Mean IOP for the overall population remained within the normal range throughout follow-up and 76.7% of patients did not require IOP-lowering therapy following treatment of the FAC implant. Sixty-nine per cent of eyes did not require additional DME treatments. Mean visual acuity in the overall population increased from 51.9 letters at baseline to 55.6 letters at month 12, with a significant increase of 2.9 letters at last observation. Patients with short-term DME experienced greater visual acuity gains than those with long-term DME. This data reinforces the safety and efficacy of the FAC treatment, and the benefit of early FAC treatment.

Uveitis is a term that encompasses any type of inflammation involving the uvea and is a leading cause of blindness worldwide (Foster et al. 2016). Uveitis accounts for approximately 10% of preventable vision loss in the United States, with a prevalence of 133 per 100,000 individuals (Foster et al. 2016; Thorne et al. 2016). There are three types of uveitis, classified according to the part of the uvea that is affected: anterior, intermediate, and posterior (NORD 2021). Posterior uveitis is the rare form of the disorder and is the type of uveitis most associated with loss of vision. Posterior uveitis may affect the retina and/or the optic nerve and may lead to permanent loss of vision. There are many infectious and non-infectious causes of posterior uveitis. Chronic non-infectious uveitis patients are more likely to have ocular comorbidities such as retinal disorders, glaucoma, and visual disturbances, as well as systemic autoimmune diseases such as rheumatoid arthritis and sarcoidosis (Foster et al. 2016; Thorne et al. 2016). The goal of treatment in chronic non-infectious *posterior segment* uveitis is to suppress inflammation, which can lead to tissue damage and subsequent permanent loss of vision (Tan et al. 2016) and ultimately preserve vision. The standard of care for noninfectious uveitis has been local and systemic corticosteroids in combination with immunomodulatory therapies.

Corticosteroids are considered the standard treatment for initial management of active inflammation in uveitis irrespective of its anatomical location. Local corticosteroids (e.g., prednisolone acetate and similar topical corticosteroids) generally do not penetrate the posterior segment in adequate concentrations to resolve vitreous inflammation, so these are usually insufficient as the primary therapy for posterior uveitis. Uveitis involving the posterior segment necessitates administration orally or via local injection. In comparison to other immunosuppressive options, steroids have a faster onset of action in controlling inflammation; however, long-term use is limited due to their side effect profile. The overall goal is to achieve long-term inflammation remission while using as few steroids as possible. Guidelines recommend the inclusion of a steroid-sparing immunosuppressive drug if, after 2 to 3 months, inflammation cannot be managed with 7.5 to 10 mg/day of prednisone (or equivalent) (Jabs 2018; Dick et al. 2018).

Immunosuppressive drugs [e.g., antimetabolites, alkylating agents, T-cell inhibitors, and tumor necrosis factor (TNF)-inhibitors] may be used in the case of corticosteroids failure or insufficient control of inflammation to prevent corticosteroid-induced side effects, and to treat high-risk uveitis syndromes. Immunosuppressive therapy is generally indicated for use in bilateral disease, active inflammation, failure to respond to oral glucocorticoid therapy, or severe disease that interferes with daily activities. Immunosuppressants, while effective, can have serious and potentially fatal side effects, such as renal and hepatic failure and bone marrow suppression.

Intraocular steroid implants were designed to provide sustained medication release, reducing the need for frequent injections. A fluocinolone acetonide (FA) implant is typically reserved for patients with a noninfectious posterior that necessitates frequent local glucocorticoid injection and for whom systemic use of glucocorticoids or other immune modulators may be particularly problematic. It should be noted that while an intraocular fluocinolone-releasing implant offers an alternative to systemic therapy, it may result

Drug and Biologic Coverage Criteria

in complications that require surgical intervention (e.g., cataract and glaucoma). In addition, its long-term safety has not been fully studied. FA intravitreal implants (Retisert; Yutiq) are indicated for treatment of chronic noninfectious uveitis affecting the posterior segment of the eye.

The 2018 Ophthalmology Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis: Fundamentals Of Care for Uveitis (FOCUS) Initiative notes that biologic and other systemic non-corticosteroid immunomodulatory agent use has increased in patients whose uveitis is not controlled with corticosteroids alone. Therapeutic corticosteroids referenced in the guidelines are periocular steroid injections, topical corticosteroids, and systemic steroids. The guidelines also note the Multicenter Uveitis Steroid Treatment (MUST) Trial 7-year study demonstrated that systemic therapy (corticosteroid-supplemented immunomodulatory therapy and biologics) improved visual outcomes, controlled inflammation, and reduced macular edema compared with an intravitreal fluocinolone acetonide implant in patients with intermediate uveitis, posterior uveitis, or panuveitis.

CONTRAINDICATIONS/EXCLUSIONS/DISCONTINUATION:

All other uses of Iluvien (fluocinolone acetonide intravitreal implant) are considered experimental/investigational and therefore, will follow Molina's Off- Label policy. Contraindications to Iluvien (fluocinolone acetonide intravitreal implant) include: Ocular or periocular infections, glaucoma, and hypersensitivity.

Exclusions/Discontinuation:

Iluvien (fluocinolone acetonide intravitreal implant) must not be administered with other intravitreal implants [i.e., Ozurdex (dexamethasone intravitreal implant), Retisert (fluocinolone acetonide intravitreal Implant)].

OTHER SPECIAL CONSIDERATIONS:

Potential adverse effects of a corticosteroid intravitreal implant include cataracts, increased intraocular pressure, or hypotony, endophthalmitis, and risk of need for additional surgical procedures.

CODING/BILLING INFORMATION

CODING DISCLAIMER. Codes listed in this policy are for reference purposes only and may not be all-inclusive or applicable for every state or line of business. Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement. Listing of a service or device code in this policy does not guarantee coverage. Coverage is determined by the benefit document. Molina adheres to Current Procedural Terminology (CPT®), a registered trademark of the American Medical Association (AMA). All CPT codes and descriptions are copyrighted by the AMA; this information is included for informational purposes only. Providers and facilities are expected to utilize industry-standard coding practices for all submissions. Molina has the right to reject/deny the claim and recover claim payment(s) if it is determined it is not billed appropriately or not a covered benefit. Molina reserves the right to revise this policy as needed.

HCPCS CODE	DESCRIPTION
J7313	Injection, fluocinolone acetonide intravitreal implant (Iluvien), 0.01 mg

AVAILABLE DOSAGE FORMS:

Iluvien IMPL 0.19MG

REFERENCES

1. Iluvien (fluocinolone acetonide intravitreal implant) 0.19 mg for intravitreal use [prescribing information].

Molina Healthcare, Inc. confidential and proprietary © 2025

This document contains confidential and proprietary information of Molina Healthcare and cannot be reproduced, distributed, or printed without written permission from Molina Healthcare. This page contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with Molina Healthcare.

Drug and Biologic Coverage Criteria

Alpharetta, GA: Alimera Sciences Inc; March 2025.

2. Adán A, Cabrera F, Figueroa MS, et al. Clinical-Decision Criteria to Identify Recurrent Diabetic Macular Edema Patients Suitable for Fluocinolone Acetonide Implant Therapy (ILUVIEN®) and Follow-Up Considerations/Recommendations. *Clin Ophthalmol.* 2020 Jul 24;14:2091-2107. doi: 10.2147/OPTH.S252359. PMID: 32801618; PMCID: PMC7398681.
3. Brambati M, Borrelli E, Capone L, et al. Changes in Macular Perfusion After ILUVIEN® Intravitreal Implant for Diabetic Macular Edema: An OCTA Study. *Ophthalmol Ther.* 2022 Apr;11(2):653-660. doi: 10.1007/s40123-022-00455-5. PMID: 35088300; PMCID: PMC8927530.
4. Campochiaro PA, Brown DM, Pearson A, FAME Study Group, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. *Ophthalmology.* 2012; 119(10):2125-2132.
5. Campochiaro PA, Brown DM, Pearson A, FAME Study Group, et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. *Ophthalmology.* 2011; 118(4):626-635.
6. Centers for Medicare and Medicaid Services (CMS). Medicare coverage database (no National Coverage Determination identified – search: fluocinolone acetonide intravitreal implant). *Cms.gov.* Accessed August 28, 2023.
7. Chakravarthy U, Taylor SR, Koch FHJ, Castro de Sousa JP, Bailey C; ILUVIEN Registry Safety Study (IRISS) Investigators Group. Changes in intraocular pressure after intravitreal fluocinolone acetonide (ILUVIEN): real-world experience in three European countries. *Br J Ophthalmol.* 2019 Aug;103(8):1072-1077. doi: 10.1136/bjophthalmol-2018-312284. PMID: 30242062; PMCID: PMC6678053.
8. ClinicalTrials.gov. Phase 4 IOP Signals Associated With ILUVIEN® (PALADIN) [ID: NCT02424019]. National Library of Medicine. Accessed August 28, 2023. <http://clinicaltrials.gov>.
9. Ehlers JP, Yeh S, Maguire MG, et al. Intravitreal Pharmacotherapies for Diabetic Macular Edema: A Report by the American Academy of Ophthalmology. *Ophthalmology.* 2022 Jan;129(1):88-99. doi: 10.1016/j.ophtha.2021.07.009. PMID: 34446301.
10. Mansour SE, Kiernan DF, Roth DB, et al. Two-year interim safety results of the 0.2 µg/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study. *Br J Ophthalmol.* 2021 Mar;105(3):414-419. doi: 10.1136/bjophthalmol-2020-315984. PMID: 32461262; PMCID: PMC7907551.
11. Rittiphairoj T, Mir TA, Li T, Virgili G. Intravitreal steroids for macular edema in diabetes. *Cochrane Database Syst Rev.* 2020 Nov 17;11(11):CD005656. doi: 10.1002/14651858.CD005656.pub3. PMID: 33206392; PMCID: PMC8095060.
12. United States Food and Drug Administration (FDA). Drugs@FDA: FDA-Approved Drugs. *Iluvien.* *FDA.gov.* Accessed August 28, 2023.
13. ElSayed, N. A., Grazia Aleppo, Bannuru, R. R., Bruemmer, D., Collins, B., Laya Ekhlaspour, ... Segal, A. R. (2023). 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2024. *Diabetes Care*, 47(Supplement_1), S231–S243. <https://doi.org/10.2337/dc24-s012>
14. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes – 2025. *Diabetes Care* 2025;48 (Suppl. 1): S252-S265. doi: <https://doi.org/10.2337/dc25-S012>
15. Multicenter Uveitis Steroid Treatment (MUST) Trial Follow-up Study Research Group. Quality of life and risks associated with systemic anti-inflammatory therapy versus fluocinolone acetonide intraocular implant for intermediate uveitis, posterior uveitis, or panuveitis: Fifty-four-month results of the multicenter uveitis steroid treatment trial and follow-up study. *Ophthalmology.* 2015 Oct;122(10):1976-86. doi: 10.1016/j.ophtha.2015.06.043. Epub 2015 Aug 19. PMID: 26298718; PMCID: PMC4581951.
16. Foster CS, Kothari S, Anesi SD, et al. The Ocular Immunology and Uveitis Foundation preferred practice patterns of uveitis management. *Surv Ophthalmol.* 2016 Jan-Feb;61(1):1-17. doi: 10.1016/j.survophthal.2015.07.001. Epub 2015 Jul 9. PMID: 26164736.
17. Thorne JE, Suhler E, Skup M, et al. Prevalence of noninfectious uveitis in the United States: A claims-based analysis. *JAMA Ophthalmol.* 2016 Nov 1;134(11):1237-1245. doi: 10.1001/jamaophthalmol.2016.3229. PMID: 27608193.
18. Tan HY, Agarwal A, Lee CS, et al. Management of noninfectious posterior uveitis with intravitreal drug therapy. *Clin Ophthalmol.* 2016 Oct 13;10:1983-2020. doi: 10.2147/OPTH.S89341. PMID: 27789936; PMCID: PMC5068474.

Molina Healthcare, Inc. confidential and proprietary © 2025

This document contains confidential and proprietary information of Molina Healthcare and cannot be reproduced, distributed, or printed without written permission from Molina Healthcare. This page contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with Molina Healthcare.

Drug and Biologic Coverage Criteria

19. Jabs DA. Immunosuppression for the Uveitides. *Ophthalmology*. 2018 Feb;125(2):193-202. doi: 10.1016/j.ophtha.2017.08.007. Epub 2017 Sep 20. PMID: 28942074; PMCID: PMC5794515.
20. Dick, A. D., Rosenbaum, J. T., Al-Dhibi, H. A., Belfort, R., Brézin, A. P., Chee, S. P., ... Akkoc, N. (2018). Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis. *Ophthalmology*, 125(5), 757–773. <https://doi.org/10.1016/j.ophtha.2017.11.017>
21. Thorne, J. E., Sugar, E. A., Holbrook, J. T., Burke, A., Altaweel, M. M., Vitale, A. T., ... Jabs, D. A. (2019). Periocular Triamcinolone vs. Intravitreal Triamcinolone vs. Intravitreal Dexamethasone Implant for the Treatment of Uveitic Macular Edema. *Ophthalmology*, 126(2), 283–295. <https://doi.org/10.1016/j.ophtha.2018.08.021>
22. National Organization for Rare Disorders (NORD). Posterior uveitis: Symptoms, causes, treatment. Updated April 21, 2021. Accessed March 5, 2024. <https://rarediseases.org/rare-diseases/posterior-uveitis/>.
23. Hossain, H. (2023, December 30). Treatment of Uveitis - American Academy of Ophthalmology EyeWiki. Retrieved October 6, 2025, from Eyewiki.org website: https://eyewiki.org/Treatment_of_Uveitis

SUMMARY OF REVIEW/REVISIONS	DATE
ANNUAL REVIEW COMPLETED- No coverage criteria changes with this annual review.	Q4 2025
REVISION- Notable revisions: Required Medical Information	Q1 2025
REVISION- Notable revisions: Coding/Billing Information Template Update Required Medical Information References	Q4 2024
MCP Conversion	Q2 2024
Policy reviewed and updated, no changes in coverage criteria, updated references	10/12/2023
Policy reviewed. References updated. Revision of criteria #3a broadened to 'a previous course of corticosteroid.' Previously 3a. Triamcinolone acetonide, intravitreal injection; Revised to: Triamcinolone acetonide, intravitreal injection previous course of corticosteroid. Reference: Fraser et al. (2020)	10/12/2022
MCPC Policy reviewed and updated, no changes in coverage criteria, updated references. IRO Peer Review 9/1/2021 by a practicing board certified in Ophthalmology physician	10/13/2021
Policy reviewed and updated, no changes in coverage criteria, updated references	Q4 2020
P&T Policy reviewed and updated, no changes in coverage criteria, updated references	Q4 2019
MCPC Policy reviewed and updated, no changes in coverage criteria, updated references	12/19/2018
MCPC New policy. IRO Peer Review 10/4/2017 by a practicing board certified in Ophthalmology, and Vitreoretinal Surgery physician.	12/13/2017